Search

Your search keyword '"Scalone S"' showing total 149 results
Start Over Author "Scalone S"
149 results on '"Scalone S"'

5. 800P Tailoring adjuvant treatments in high-risk early stage endometrial cancer: Clinical outcomes of sequential chemoradiation in a real-word scenario

Author

de Scordilli, M., primary, Bartoletti, M., additional, Palazzari, E., additional, Mazzeo, R., additional, Michelotti, A., additional, Alberti, M., additional, Gerratana, L., additional, Nicoloso, M.S., additional, Corsetti, S., additional, Scalone, S., additional, Gigante, M., additional, Forte, S., additional, Clemente, N., additional, Del Fabro, A., additional, Lucia, E., additional, Ganis, A., additional, Giorda, G., additional, Canzonieri, V., additional, Sorio, R., additional, and Puglisi, F., additional

Published
2021
Full Text
View/download PDF

7. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

Author

Ménard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M.L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandarà, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., Montagna, E., Perrone, F., De Matteis, A., Sapino, A., Donadio, M., Battelli, N., Santinelli, A., Pavesi, L., Lanza, A., Zito, F.A., Labriola, A., Aiello, R.A., Caruso, M., Zanconati, F., Mustacchi, G., Barbareschi, M., Frisinghelli, M., Russo, R., and Carrillo, G.

Published
2008
Full Text
View/download PDF

9. 842P Carboplatin-induced thrombocytopenia in ovarian cancer: A focus on predictive factors

Author

Mazzeo, R., primary, Bartoletti, M., additional, de Scordilli, M., additional, Alberti, M., additional, Michelotti, A., additional, Lisanti, C., additional, Parnofiello, A., additional, Bertoli, E., additional, Buriolla, S., additional, Pelizzari, G., additional, Cortiula, F., additional, Basile, D., additional, Gagno, S., additional, Scalone, S., additional, Nicoloso, M.S., additional, Corsetti, S., additional, Lombardi, D., additional, Gerratana, L., additional, Sorio, R., additional, and Puglisi, F., additional

Published
2020
Full Text
View/download PDF

17. EP795 Searching for the best maintenance therapy in platinum-sensitive recurrent ovarian cancer: bevacizumab or PARP-inhibitors? A network meta-analysis

Author

Bartoletti, M, primary, Pelizzari, G, additional, Bortot, L, additional, Giavarra, M, additional, Vitale, MG, additional, Andreotti, V, additional, Parnofiello, A, additional, Scalone, S, additional, Lombardi, D, additional, Nicoloso, M, additional, Bozza, C, additional, Poletto, E, additional, Sacco, C, additional, Andreetta, C, additional, Sorio, R, additional, and Puglisi, F, additional

Published
2019
Full Text
View/download PDF

18. EP806 First insight of a tailoring chemotherapy intensity regimen in a real life cohort of elderly patients with ovarian cancer: the CIRCE study

Author

Bortot, L, primary, Bartoletti, M, additional, Basile, D, additional, Gerratana, L, additional, Corvaja, C, additional, Lisanti, C, additional, Pelizzari, G, additional, Garattini, SK, additional, Garutti, M, additional, Buriolla, S, additional, Da Ros, L, additional, Bolzonello, S, additional, Di Nardo, P, additional, Spazzapan, S, additional, Nicoloso, MS, additional, Scalone, S, additional, Lombardi, D, additional, Giorda, G, additional, Sorio, R, additional, and Puglisi, F, additional

Published
2019
Full Text
View/download PDF

20. Advanced ovarian cancer: Is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?

Author

Bartoletti, M., primary, Gagno, S., additional, Poletto, E., additional, Garziera, M., additional, Scalone, S., additional, Dreussi, E., additional, Zanusso, C., additional, Roncato, R., additional, Cecchin, E., additional, De Mattia, E., additional, Sorio, R., additional, Giorda, G., additional, Quartuccio, L., additional, De Vita, S., additional, Romualdi, C., additional, Puglisi, F., additional, and Toffoli, G., additional

Published
2019
Full Text
View/download PDF

24. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Author

Papaldo, P., Lopez, M., Cortesi, Enrico, Cammilluzzi, E., Antimi, M., Terzoli, E., Lepidini, G., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Nistico, C., Carlini, P., Conti, F., Di Lauro, L., Botti, C., Vitucci, C., Fabi, A., Giannarelli, D., Marolla, P., Di Maio, M., Perrone, F., Gallo, C., Iaffaioli, R. V., Manzione, L., Piantedosi, F. V., Cigolari, S., Illiano, A., Barbera, S., Robbiati, S. F., Piazza, E., Ianniello, G. P., Frontini, L., Veltri, E., Castiglione, F., Rosetti, F., De Maio, E., Maione, P., Gridelli, C., Rossi, A., Barletta, E., Barzelloni, M. L., Signoriello, G., Bilancia, D., Dinota, A., Rosati, G., Germano, D., Lamberti, A., Pontillo, V., Brancacio, L., Crispino, C., Esposito, M., Battiloro, C., Tufano, G., Cioffi, A., Guardasole, V., Angelini, V., Guidetti, G., Renda, F., Romano, F., Volpintesta, A., Sannicolo, M., Filipazzi, V., Esani, G., Gambaro, A., Ferrario, S., Tinessa, V., Caprio, M. G., Zonato, S., Cabiddu, M., Raina, A., D'Aprile, M., Pistillucci, G., Porcile, G., Ostellino, O., Vinante, O., Azzarello, G., Gebbia, V., Borsellino, N., Testa, A., Gasparini, G., Morabito, A., Gattuso, D., Romito, S., Carrozza, F., Fava, S., Calcagno, A., Grimi, E., Bertetto, O., Ciuffreda, L., Parello, G., Maiorino, L., Santoro, A., Santoro, M., Failla, G., Aiello, R. A., Bearz, A., Sorio, R., Scalone, S., Clerici, M., Bollina, R., Belloni, P., Sacco, C., Sibau, A., Adamo, V., Altavilla, G., Scimone, A., Spatafora, M., Bellia, V., Hopps, M. R., Monfardini, S., Favaretto, A., Stefani, M., Corradini, G. M., Pavia, G., Scagliotti, G., Novello, S., Selvaggi, G., Tonato, M., Darwish, S., Michetti, G., Belometti, M. O., Labianca, R., Quadri, A., De Marinis, F., Migliorino, M. R., Martelli, O., Colucci, G., Galetta, D., Giotta, F., Isa, L., Candido, P., Rossi, N., Calandriello, A., Ferrau, F., Malaponte, E., Barni, S., Cazzaniga, M., Gebbia, N., Valerio, Mr, Belli, M., Colantuoni, G., Capuano, M. A., Angiolillo, M., Sollitto, F., Ardizzoia, A., Luporini, G., Locatelli, M. C., Pari, F., Aitini, E., Pedicini, T., Febbraro, A., Zollo, C., Di Costanzo, F., Bartolucci, R., Gasperoni, S., Gaion, F., Palazzolo, G., Galligioni, E., Caffo, O., Cortesi, E., D'Auria, G., Curcio, C., Vasta, M., Bumma, C., Celano, A., Bretti, S., Nettis, G., Anselmo, A., Mattioli, R., Aschelter, A., and Foa, P.

Subjects
Adult, Cancer Research, medicine.medical_specialty, Indazoles, Filgrastim, Cyclophosphamide, medicine.medical_treatment, Breast Neoplasms, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Humans, Survival rate, Aged, Epirubicin, Chemotherapy, business.industry, Lonidamine, Middle Aged, medicine.disease, Metastatic breast cancer, Recombinant Proteins, Granulocyte colony-stimulating factor, Surgery, Survival Rate, Oncology, chemistry, Female, business, Follow-Up Studies, medicine.drug
Abstract

Purpose: Lonidamine (LND) can enhance the activity of anthracyclines in patients with metastatic breast cancer. A multicenter, prospective, randomized trial was designed to determine whether the association of LND with high-dose epirubicin plus cyclophosphamide (EC) could improve disease-free survival (DFS) in patients with early breast cancer (BC) compared with EC alone. Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity. Patients and Methods: From October 1991 to April 1994, 506 patients with stage I/II BC were randomly assigned to four groups: (A) epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on day 1 every 21 days for four cycles (124 patients); (B) EC plus LND 450 mg/d administered orally (125 patients); (C) EC plus G-CSF administered subcutaneously (129 patients); (D) EC plus LND plus G-CSF (128 patients). Results: Median follow-up was 55 months. Five-year DFS rate was similar for LND (B+D groups; 69.6%) versus non-LND arms (A+C groups; 70.3%) and G-CSF (C+D groups; 67.2%) versus non–G-CSF arms (A+B groups; 72.9%). Five-year overall survival (OS) was comparable in LND (79.1%) versus non-LND arms (81.3%) and in G-CSF (80.6%) versus non–G-CSF arms (79.6%). DFS and OS distributions in LND and G-CSF arms did not change according to tumor size, node, receptor, and menopausal status. G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity (98.1% v 95.5% for C+D and A+B groups, respectively). Conclusion: EC is active and well tolerated in patients with early breast cancer. The addition of LND or G-CSF does not improve DFS or OS.

Published
2003
Full Text
View/download PDF

25. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

Author

Ménard, S, Balsari, A, Tagliabue, E, Camerini, T, Casalini, P, Bufalino, R, Castiglioni, F, Carcangiu, Ml, Gloghini, A, Scalone, S, Querzoli, P, Lunardi, M, Molino, A, Mandarã, M, Mottolese, M, Marandino, F, Venturini, M, Bighin, C, Cancello, G, Montagna, E, Perrone, F, DE MATTEIS, A, Sapino, A, Donadio, M, Battelli, N, Santinelli, A, Pavesi, L, Lanza, A, Zito, Fa, Labriola, A, Aiello, Ra, Caruso, M, Zanconati, Fabrizio, Mustacchi, Giorgio, Barbareschi, M, Frisinghelli, M, Russo, R, Carrillo, G, Omero, Group, Ménard, S, Balsari, A, Tagliabue, E, Camerini, T, Casalini, P, Bufalino, R, Castiglioni, F, Carcangiu, Ml, Gloghini, A, Scalone, S, Querzoli, P, Lunardi, M, Molino, A, Mandarã, M, Mottolese, M, Marandino, F, Venturini, M, Bighin, C, Cancello, G, Montagna, E, Perrone, F, DE MATTEIS, A, Sapino, A, Donadio, M, Battelli, N, Santinelli, A, Pavesi, L, Lanza, A, Zito, Fa, Labriola, A, Aiello, Ra, Caruso, M, Zanconati, Fabrizio, Mustacchi, Giorgio, Barbareschi, M, Frisinghelli, M, Russo, R, Carrillo, G, and Omero, Group

Subjects
Oncology, medicine.medical_specialty, Pathology, Antineoplastic Agents, Hormonal, Receptor, ErbB-2, medicine.medical_treatment, Receptor expression, HeceptTest, Breast Neoplasms, Disease-Free Survival, NO, Breast cancer, Internal medicine, HER2, Antineoplastic Combined Chemotherapy Protocols, Progesterone receptor, medicine, Humans, HER2, HeceptTest, prognosis, therapy, skin and connective tissue diseases, neoplasms, Mastectomy, Retrospective Studies, Settore MED/04 - Patologia Generale, therapy, HerceptTest, prognosis, business.industry, Cancer, Hematology, Middle Aged, medicine.disease, Combined Modality Therapy, Immunohistochemistry, Female, Breast disease, business, Breast carcinoma, prognosi
Abstract

Background The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. Patients and methods A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. Results Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. Conclusions The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.

Published
2008

28. Pre-emptive pharmacogenetic testing implementation for chemotherapy dosage optimization: the translational experience at CRO of Aviano

Author

Cecchin, E., primary, Giodini, L., additional, Buonadonna, A., additional, Berretta, M., additional, De Paoli, A., additional, Scalone, S., additional, Miolo, G., additional, Mini, E., additional, Nobili, S., additional, Mazzei, T., additional, Lonardi, S., additional, Zagonel, V., additional, Pella, N., additional, Fasola, G., additional, Tirelli, U., additional, Montico, M., additional, Roncato, R., additional, and Toffoli, G., additional

Published
2015
Full Text
View/download PDF

30. Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy

Author

Muraro, E, primary, Comaro, E, additional, Talamini, R, additional, Turchet, E, additional, Miolo, G, additional, Scalone, S, additional, Militello, L, additional, Lombardi, D, additional, Spazzapan, S, additional, Perin, T, additional, Massarut, S, additional, Crivellari, D, additional, Dolcetti, Riccardo, additional, and Martorelli, D, additional

Published
2015
Full Text
View/download PDF

32. Supportive care in patients with advanced non-small-cell lung cancer

Author

DI MAIO, Massimo, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, De Maio, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolò, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, V, Altavilla, G, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, Giorgio Vittorio, Novello, Silvia, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, De Marinis, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferraù, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, Di Costanzo, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nisticò, C, Aschelter, A, Foa, P., DI MAIO, M, Perrone, F, Gallo, Ciro, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, and Gridelli, C.

Subjects
Adult, Male, concomitant drugs, Cancer Research, medicine.medical_specialty, Aging, Palliative care, Lung Neoplasms, medicine.medical_treatment, Vinorelbine, Vinblastine, Deoxycytidine, Clinical, Quality of life, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, polypharmacotherapy, medicine, Humans, Lung cancer, Survival rate, Aged, Randomized Controlled Trials as Topic, Aged, 80 and over, Chemotherapy, Performance status, business.industry, Palliative Care, Middle Aged, medicine.disease, Gemcitabine, Surgery, Survival Rate, supportive care, lung cancer, Oncology, Concomitant, Quality of Life, Antiemetics, Female, Cisplatin, business, medicine.drug
Abstract

The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

Published
2004

33. Supportive care in patients with advanced non small cell lung cancer

Author

DI MAIO, M, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolo, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, Vincenzo, Altavilla, Giuseppe, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, G, Novello, S, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, DE MARINIS, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferrau, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, DI COSTANZO, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nistico, C, Aschelter, A, and Foa, P.

Published
2003

35. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

Author

Lorusso, D, Ferrandina, Maria Gabriella, Pignata, S, Ludovisi, Manuela, Viganò, R, Scalone, S, Scollo, P, Breda, E, Pietragalla, A, Scambia, Giovanni, Ferrandina, Maria Gabriella (ORCID:0000-0003-4672-4197), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Lorusso, D, Ferrandina, Maria Gabriella, Pignata, S, Ludovisi, Manuela, Viganò, R, Scalone, S, Scollo, P, Breda, E, Pietragalla, A, Scambia, Giovanni, Ferrandina, Maria Gabriella (ORCID:0000-0003-4672-4197), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity.

Published
2010

36. Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

Author

Miolo, G, Canzonieri, V, De Giacomi, C, Della Puppa, L, Dolcetti, R, Lombardi, D, Perin, T, Scalone, S, Veronesi, A, Viel, A, Miolo, G, Canzonieri, V, De Giacomi, C, Della Puppa, L, Dolcetti, R, Lombardi, D, Perin, T, Scalone, S, Veronesi, A, and Viel, A

Abstract

BACKGROUND: BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers. METHODS: Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay. RESULTS: A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively. CONCLUSION: Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.

Published
2009

42. Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Author

Muraro, E., Comaro, E., Talamini, R., Turchet, E., Miolo, G., Scalone, S., Militello, L., Lombardi, D., Spazzapan, S., Perin, T., Massarut, S., Crivellari, D., Dolcetti, Riccardo, and Martorelli, D.

Subjects
INTERLEUKIN-12, BREAST cancer research, CANCER chemotherapy, PACLITAXEL synthesis, EPIRUBICIN
Abstract

Background: Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together with the immune-modulating activities of NC drugs suggest a potential contribution of host immunity in mediating clinical responses. We thus performed an extensive immunomonitoring in locally advanced BC patients undergoing NC to identify immunological correlates of pCR induction. Methods: The immune profile of 40 HER2-positive and 38 HER2-negative BC patients was characterized at diagnosis and throughout NC (Paclitaxel and Trastuzumab, or Docetaxel and Epirubicin, respectively). The percentages of circulating immune cell subsets including T and B lymphocytes, Natural Killer (NK) cells, regulatory T cells, T helper 17 lymphocytes, were quantified by multiparametric flow cytometry. NK cells functional activity was evaluated through the analysis of NF-kB nuclear translocation by Multispectral flow cytometry, and with the in vitro monitoring of Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC). CD8+ T cell responses against six different tumor-associated antigens (TAA) were characterized by IFN-γ ELISPOT and IFN-γ/IL-2 DualSpot assays. Results: After NC, HER2-positive patients showed a significant increase in the number of NK cells and regulatory T cells irrespective of the pathological response, whereas patients undergoing a pCR disclosed higher percentages of T helper 17 cells. Notably, a significant increase in the number of activated NK cells was observed only in HER2-positive patients achieving a pCR. Characterization of anti-tumor T cell responses highlighted sustained levels of CD8+ T cells specific for survivin and mammaglobin-A throughout NC in patients undergoing a pCR in both arms. Moreover, HER2-positive patients achieving a pCR were characterized by a multi-epitopic and polyfunctional anti-tumor T cell response, markedly reduced in case of partial response. Conclusions: These results indicate that maintenance of functional T cell responses against selected antigens and improvement of NK cell proficiency during NC are probably critical requirements for pCR induction, especially in HER2-positive BC patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results